Study confirms efficacy of NewLink Genetics ebola vaccine

December 26, 2016

A study published last Thursday in  found the ebola vaccine can provide up to 100% protection against onset of, one of the two most common strains of ebola, responsible for most of the cases observed in humans. Iowa-based NewLink Genetics, which owns the rights to rVSV-ZEVOB, on Friday announced hope the US Food and Drug Administration (FDA) would award them a in recognition of their work with the vaccine. The study's findings also show the vaccine is effective post-exposure, which makes it suitable for, the anti-outbreak strategy used in the study, in which everyone who has come into contact with a confirmed case is vaccinated to prevent the illness from spreading.

NewLink's chief scientific officer for infectious diseases, Thomas Monath, said the FDA would likely approve the vaccine quickly, with large-scale production as early as 2018.

This might not be the only NewLink project to be waved to the front of the line. Priority review vouchers are awarded by the FDA as a means of providing an incentive for private industry to focus on tropical diseases and rare conditions. Any company that sees an eligible vaccine or treatment formally licensed can receive a voucher for fast-track FDA review on a future project. They can either keep the voucher for their own use or sell it. According to Monath, they can sell for 100–300 million, and NewLink would share the money from any such sale with, which currently holds the license on the vaccine.

rVSV-ZEVOB was initially developed by the of  and the. It is a live  virus based on  virus. Although it is harmless to humans, it has been engineered to one of the same surface marker proteins as the Zaire ebolavirus, which trains the host's  to recognize both the vaccine and the true virus.

US President Barack Obama added ebola to the priority review voucher program in December 2014 during the in West Africa.